{"entity":{"id":"dancey-janet","kind":"person","name":"Janet Dancey","aka":[],"tldr":"Runs Canada's academic cancer trials network, which has led practice-changing trials from PA.3 to CO.17 and beyond.","summary":"Janet Dancey is Director of the Canadian Cancer Trials Group and Professor of Oncology at Queen's University. She runs Canada's academic cancer trials network, which has led practice-changing trials from PA.3 to CO.17, coordinating national and international studies across cancers, and she previously led precision medicine efforts at the Ontario Institute for Cancer Research and drug development at the US National Cancer Institute. Her publications include an adaptive phase 2 trial using circulating tumour DNA response after pembrolizumab in non-small-cell lung cancer, a review of mTOR signalling and drug development, and the iRECIST guidelines for response criteria in immunotherapy trials. Her interests are clinical trials, precision oncology and cooperative groups.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Janet_Dancey","links":[{"label":"Canadian Cancer Trials Group","url":"https://www.ctg.queensu.ca"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dancey%20J%5BAuthor%5D%20Canadian%20Cancer%20Trials%20Group"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["cgp"],"targets":[],"drugs":[],"companies":["cctg"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Canadian Cancer Trials Group; Professor of Oncology, Queen's University","institutionId":"cctg","specialisms":["Clinical trials","Precision oncology","Drug development","Cooperative groups"],"profiles":[{"label":"Canadian Cancer Trials Group","url":"https://www.ctg.queensu.ca"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dancey%20J%5BAuthor%5D%20Canadian%20Cancer%20Trials%20Group"}],"papers":[{"title":"ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results","journal":"Nature Medicine","year":2023,"doi":"10.1038/s41591-023-02598-9"},{"title":"mTOR signaling and drug development in cancer","journal":"Nature Reviews Clinical Oncology","year":2010,"doi":"10.1038/nrclinonc.2010.21"},{"title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","journal":"The Lancet Oncology","year":2017,"doi":"10.1016/s1470-2045(17)30074-8"},{"title":"CHALLENGE: a structured exercise programme after chemotherapy improves survival in colon cancer","journal":"New England Journal of Medicine","year":2025,"url":"https://doi.org/10.1056/NEJMoa2502760","doi":"10.1056/NEJMoa2502760"}]},"route":"/people/dancey-janet/","neighbours":{"technology":[{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/"}],"company":[{"id":"cctg","kind":"company","name":"Canadian Cancer Trials Group (CCTG)","route":"/companies/cctg/"}],"paper":[{"id":"paper-challenge-exercise-nejm-2025","kind":"paper","name":"CHALLENGE: a structured exercise programme after chemotherapy improves survival in colon cancer","route":"/key-papers/paper-challenge-exercise-nejm-2025/"}],"institution":[{"id":"oicr","kind":"institution","name":"Ontario Institute for Cancer Research","route":"/institutions/oicr/"}]}}